Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of α(1)-adrenergic receptor antibodies

Item Type:Article
Title:Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of α(1)-adrenergic receptor antibodies
Creators Name:Pohlmann, A., Karczewski, P., Ku, M.C., Dieringer, B., Waiczies, H., Wisbrun, N., Kox, S., Palatnik, I., Reimann, H.M., Eichhorn, C., Waiczies, S., Hempel, P., Lemke, B., Niendorf, T. and Bimmler, M.
Abstract:Cerebrovascular abnormality is frequently accompanied by cognitive dysfunctions, such as dementia. Antibodies against the alpha1-adrenoceptor (alpha1-AR) can be found in patients with Alzheimer's disease with cerebrovascular disease, and have been shown to affect the larger vessels of the brain in rodents. However, the impact of alpha1-AR antibodies on the cerebral vasculature remains unclear. In the present study, we established a neuroimaging method to measure the relative cerebral blood volume (rCBV) in small rodents with the ultimate goal to detect changes in blood vessel density and/or vessel size induced by alpha1-AR antibodies. For this purpose, mapping of R2 * and R2 was performed using MRI at 9.4 T, before and after the injection of intravascular iron oxide particles (ferumoxytol). The change in the transverse relaxation rates (DeltaR2 *, DeltaR2) showed a significant rCBV decrease in the cerebrum, cortex and hippocampus of rats (except hippocampal DeltaR2), which was more pronounced for DeltaR2 * than for DeltaR2. Immunohistological analyses confirmed that the alpha1-AR antibody induced blood vessel deficiencies. Our findings support the hypothesis that alpha1-AR antibodies lead to cerebral vessel damage throughout the brain, which can be monitored by MRI-derived rCBV, a non-invasive neuroimaging method. This demonstrates the value of rCBV estimation by ferumoxytol-enhanced MRI at 9.4 T, and further underlines the significance of this antibody in brain diseases involving vasculature impairments, such as dementia.
Keywords:MRI, Cerebral Blood Volume (CBV), Ferumoxytol, Ultrasmall Superparamagnetic Iron Oxide (USPIO), alpha1-Adrenergic Receptor, Antibody, Animals, Rats
Source:NMR in Biomedicine
ISSN:0952-3480
Publisher:Wiley-Blackwell
Volume:27
Number:9
Page Range:1085-1093
Date:September 2014
Official Publication:https://doi.org/10.1002/nbm.3160
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library